CAS 496775-62-3|Eltrombopag olamine

Introduction：Basic information about CAS 496775-62-3|Eltrombopag olamine, including its chemical name, molecular formula, synonyms, physicochemical properties, and safety information, etc.

Table of Contents

1. Names
2. Eltrombopag olamine BiologicalActivity
3. Chemical & Physical Properties
4. Synonyms

Common Name	Eltrombopag olamine
CAS Number	496775-62-3	Molecular Weight	564.633
Density	/	Boiling Point	/
Molecular Formula	C₂₉H₃₆N₆O₆	Melting Point	/
MSDS	/	Flash Point	/

Names

Name	Eltrombopag olamine
Synonym	More Synonyms

Eltrombopag olamine BiologicalActivity

Description	Eltrombopag is a thrombopoietin-receptor agonist used to treat low blood platelet counts with chronic immune thrombocytopenia.
Related Catalog	Signaling Pathways >>Immunology/Inflammation >>Thrombopoietin ReceptorResearch Areas >>Cardiovascular Disease
References	[1]. Erickson-Miller CL, et al. Preclinical activity of eltrombopag (SB-497115), an oral, nonpeptide thrombopoietin receptor agonist. Stem Cells. 2009 Feb;27(2):424-30. [2]. Erickson-Miller CL, et al. Discovery and characterization of a selective, nonpeptidyl thrombopoietin receptor agonist. Exp Hematol. 2005 Jan;33(1):85-93. [3]. McHutchison JG, et al. Eltrombopag for thrombocytopenia in patients with cirrhosis associated with hepatitis C. N Engl J Med. 2007 Nov 29;357(22):2227-36. [4]. Jenkins JM, et al. Phase 1 clinical study of eltrombopag, an oral, nonpeptide thrombopoietin receptor agonist. Blood. 2007 Jun 1;109(11):4739-41. [5]. Saleh MN, et al. Safety and efficacy of eltrombopag for treatment of chronic immune thrombocytopenia: results of the long-term, open-label EXTEND study. Blood. 2013 Jan 17;121(3):537-45.

Description

Eltrombopag is a thrombopoietin-receptor agonist used to treat low blood platelet counts with chronic immune thrombocytopenia.

Related Catalog

Signaling Pathways >>Immunology/Inflammation >>Thrombopoietin ReceptorResearch Areas >>Cardiovascular Disease

References

[1]. Erickson-Miller CL, et al. Preclinical activity of eltrombopag (SB-497115), an oral, nonpeptide thrombopoietin receptor agonist. Stem Cells. 2009 Feb;27(2):424-30.

[2]. Erickson-Miller CL, et al. Discovery and characterization of a selective, nonpeptidyl thrombopoietin receptor agonist. Exp Hematol. 2005 Jan;33(1):85-93.

[3]. McHutchison JG, et al. Eltrombopag for thrombocytopenia in patients with cirrhosis associated with hepatitis C. N Engl J Med. 2007 Nov 29;357(22):2227-36.

[4]. Jenkins JM, et al. Phase 1 clinical study of eltrombopag, an oral, nonpeptide thrombopoietin receptor agonist. Blood. 2007 Jun 1;109(11):4739-41.

[5]. Saleh MN, et al. Safety and efficacy of eltrombopag for treatment of chronic immune thrombocytopenia: results of the long-term, open-label EXTEND study. Blood. 2013 Jan 17;121(3):537-45.

Chemical & Physical Properties

Molecular Formula	C₂₉H₃₆N₆O₆
Molecular Weight	564.633
Exact Mass	564.269653
PSA	209.05000
LogP	3.12780
Storage condition	-20℃

Synonyms

Eltrombopag olamine

Revolade

Promacta

UNII-4U07F515LG

[1,1'-Biphenyl]-3-carboxylic acid, 3'-[(2Z)-2-[1-(3,4-dimethylphenyl)-1,5-dihydro-3-methyl-5-oxo-4H-pyrazol-4-ylidene]hydrazinyl]-2'-hydroxy-, compd. with 2-aminoethanol (1:2)

3'-{(2Z)-2-[1-(3,4-Dimethylphenyl)-3-methyl-5-oxo-1,5-dihydro-4H-pyrazol-4-ylidene]hydrazino}-2'-hydroxy-3-biphenylcarboxylic acid - 2-aminoethanol (1:2)

Eltrombopag diethanolamine salt

Eltrombopag Impurity 1

Eltrombopag (Olamine)

Recommended......